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Follicular lymphoma (FL) is defined as a neoplasm ofgerminal center B cells, usually with a folliculargrowth pattern. The neoplastic population typically
consists predominantly of centrocytes, the resting cells
present in the light zone of normal germinal centers, and
relatively few centroblasts, the more immature and rapid-
ly proliferating cells of the germinal center dark zone. FL
cells usually express Bcl6, CD10 and other proteins that
are also expressed in germinal center B cells. A major dif-
ference between FL cells and germinal center B cells is the
former’s expression of the anti-apoptotic bcl2 protein,
which is caused by the characteristic translocation t(14;18)
involving the BCL2 gene or its variants t(2;18) and t(18;22)
and enables the cells to survive in the absence of antigenic
stimulation. This results in accumulation of non-proliferat-
ing centrocytes with a minority of proliferating centrob-
lasts and a low proliferation index with Ki-67 staining.
According to the pathologist, this configuration is “trans-
lated” into a low histological grade of the lymphoma.
Although FL is typically widespread at the time of the
diagnosis and indolent in its clinical evolution, it has long
been recognized that clinical aggressiveness and risk of
transformation to diffuse large B-cell lymphoma (DLBCL)
increases proportionally to the numbers of large cells (cen-
troblasts) and the proliferation fraction.1-3 Pathological
classification schemes developed largely in the USA
(where FL is very common) suggested dividing FL into
three subtypes (or grades), based on the number of large
cells.4 In contrast, the European Kiel classification5 consid-
ered that cases containing both centrocytes (usually pre-
dominant) and centroblasts comprised one disease (cen-
troblastic/centrocytic lymphoma, equivalent to the World
Health Organization FL1-2, and possibly 3A), while those
in which centroblasts predominated were considered a
follicular variant of centroblastic lymphoma (a morpholog-
ical variant of DLBCL). The WHO classifications of 2001
and 20086 recognized three grades - FL1-2, FL3A and FL3B
(Table 1), based on the number of centroblasts present per
high power field;  the difference between FL3A and FL3B
is the presence of a mixture of centrocytes and centrob-
lasts in FL3A and the presence of follicles existing exclu-
sively of centroblasts, immunoblasts, or both in FL3B. The
continuation of a grading system is supported by the fact
that several studies suggested that grades predict outcome,
higher grades being associated with poor clinical outcome
and more rapid progression to DLBCL. However, the
reproducibility of grading is low, and it has not been easily
replaced by immunohistochemistry for Ki67/MIB1 (prolif-
eration index).
Several studies have tried to address the issue of
whether there are biological differences between typical
low-grade FL1-2 and FL with increased centroblasts (grade
3), and between FL3A and FL3B.7-11 Several recent studies
suggest that higher grade FL, in particular FL3B, are differ-
ent with regards to genetic, immunophenotypic and clini-
cal features from the prototypic FL1-2. While FL1-2 lym-
phomas are relatively homogeneous (expression of CD10,
BCL2 and BCL6, and carrying a t(14;18) in 90% of the
cases), FL3A and, in particular, FL3B are more heteroge-
neous with respect to immunophenotype, genetic abnor-
malities, and gene expression. Individual studies have
taken different approaches to this issue but encountered
the same problem: some cases of FL3B have many features
in common with FL1-2, whereas other cases have more in
common with DLBCL (Table 2). 
Any study on the biology of FL3B is complicated by rel-
atively simple factors related to the definition itself and
purely histopathological aspects. First, some cases of FL
contain large centrocytes (large cleaved cells) or small cen-
troblasts that may be interpreted differently by individual
pathologists, so that the border between FL3A and FL3B
may be blurred.  Second, some cases of FL show consider-
able heterogeneity from area to area. Third, poor tissue
handling, fixation or technical processing problems may
introduce artifacts that interfere with grading. Fourth, in
many cases of FL3B the biopsy contains diffuse areas with
sheets of centroblasts, consistent with DLBCL. The pres-
ence of such diffuse areas is associated with a worse out-
come,2,12 and the WHO classification requires that a sepa-
rate diagnosis of DLBCL be made in such cases (Table 2).
However, this interpretation is not unambiguous, and in
addition, areas of DLBCL may be easily missed in small
biopsies. Another problem is that in some cases of FL
there are discrepancies between the cellular composition
and the Ki67 proliferation index.13,14 Some cases of FL1/2
may show a majority of cells being in cycle, whereas some
FL3B cases have a relatively low proliferation index.
Finally, cases of FL3B with a history of FL1-2 were some-
times included in published series.  
The problems regarding the histological definition of
FL3B are illustrated in the paper by Horn et al. published in
Table 1. Grading of follicular lymphoma (WHO 2008).5
Grade Definition
Grade 1-2 0-15 centroblasts / 0.159 mm2
Grade 1 0-5 centroblasts / 0.159 mm2
Grade 2 5-15 centroblasts / 0.159 mm2
Grade 3 >15 centroblasts / 0.159 mm2
Grade 3A centrocytes present
Grade 3B solid sheets of centroblasts
DLBCL with follicular component diffuse area with solid sheets of 
centroblasts outside histologically 
or immunophenotypically (CD21,
CD23+ FDC) recognizable follicles
this issue of Haematologica.15 These authors collected a
large series of 23 cases of FL3B and compared the
immunophenotypic and genetic features of these cases
with other cases of FL, including FL3A, FL3B with DLBCL,
cases in which a distinction between FL3A and FL3B was
not possible (FL3U), cases of FL consisting of large centro-
cytes or having a high proliferation fraction, and cases of
typical FL1-2. Interestingly, even after introducing these six
different categories, it appeared that while FL1-2 was very
homogeneous, all other categories, including FL3A and
FL3B, remained heterogeneous with regards to most fea-
tures analyzed. Half of the FL3B cases expressed the germi-
nal center marker CD10, as FL1-2 and FL3A do, while half
lacked CD10 and expressed MUM1/IRF4, a post-germinal
center marker not seen in FL1-3A. Only 9% of FL3B con-
tained a BCL2 break, in contrast to 88% of FL1-2; 17% of
FL3B cases had a BCL6 break and 22% a MYC break,
which were not seen in FL1-2. However, FL3A was also
not homogenous; only 58% had a BCL2 break and 22%
had a BCL6 break, the latter being similar to the frequency
in FL3B. FL3U, in which stratification as 3A or 3B was not
possible by morphological criteria, was not surprisingly
heterogeneous, with some cases resembling FL1-2 and oth-
ers FL3B. Both FL3A and FL3B differed importantly from
DLBCL with a component of FL3B, which rarely expressed
CD10, often expressed MUM1/IRF4, and had a BCL6
break in 50% of cases, similar to DLBCL without a partial-
ly follicular pattern. Interestingly, in all categories, includ-
ing those of FL1-2 with a high proliferation fraction, when
MYC breaks occurred, they were often seen together with
BCL2 or less often, BCL6 breaks, suggesting that these are
events associated with progression or transformation to a
higher-grade process.
What can we conclude for clinical practice from this
study? Unfortunately clinical follow-up data are not avail-
able on the patients studied. The biological heterogeneity
of all categories of FL3 suggests that a simple system of
subclassification of this category may not be possible. No
clinical differences have been found to date between cases
of FL3A and FL3B without a component of DLBCL treated
with current anthracycline-containing regimens, so that
the clinical relevance of this distinction is not evident.15,16
In the absence of clinical follow-up data from the series
reported by Horn et al., it is not possible to determine
whether separating FL1-2 with a high proliferation index
or large centrocytes from typical FL1-2 is clinically rele-
vant. It is also not possible to determine from this study
whether FL3A (or for that matter FL3B) with a FL1-2 bio-
logical profile (CD10+, t(14;18)+) should be folded in with
FL1-2 or kept as FL3, because the presence of numerous
centroblasts may still predict a more aggressive course
than that associated with FL1-2. 
An important question is whether the histological grad-
ing system could be replaced or supplemented by a genet-
ically oriented classification system, for instance by sepa-
rating t(14;18)-positive FL from translocation-negative
ones. Such an approach is appealing and has been fol-
lowed in several studies.11,17-24 However, while FL that lack
a t(14;18) have clinical and pathological differences from
those with the translocation, the category of t(14;18)-neg-
ative FL is not homogeneous. Nonetheless, it might be
useful to identify such cases for further study or individu-
alized treatment. Importantly, even within the category of
t(14;18)-positive FL, a grading system might still be desir-
able to identify cases with increased centroblasts (FL3A or
B) or a high proliferation index, which may still have a
more aggressive clinical behavior than grade 1-2 cases.
Thus, stratification of FL based solely on genetic features
does not seem practical at present.
In summary, the study by Horn et al. has demonstrated
the relative (and not unexpected) immunophenotypic and
genetic homogeneity of typical FL1-2, including those
cases with a high proliferation fraction or large centro-
cytes. It is also clear that FL3B with a component of
DLBCL is genetically and immunophenotypically similar
to DLBCL, and distinct from any of the FL categories. FL3,
regardless of the exact proportion of centroblasts, is het-
erogeneous. While the majority of cases of FL3A have a
germinal center B-cell immunophenotype, similar to FL1-
2, 40-50% lack BCL2 rearrangement or expression. While
only rare cases of FL3B have a BCL2 break, expression of
CD10 or Bcl2 was seen in about 40%. Assessment of
BCL2, BCL6, and MYC breaks as well as expression of
CD10 and Mum1/IRF4 could be used to identify FL3 cases
that are biologically closer to FL1-2 and those that are dis-
tinct; however, clinical data to support the need for this
distinction in practice are lacking.
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Table 2. Pathology of FL3B.
                                          N.        CD10        Bcl6        MUM1     Bcl2             BCL2                  BCL6                    MYC                 Gene             Ref.
                                                      (%)           (%)             (%)          (%)       breakpoint (%)    breakpoint (%)     breakpoint (%)    expression 
Bosga -Bouwer *                    21             43               100                nd             67                      33                             33                               14                          nd                 [9;10]
Katzenberger                           5              60                60                 bd             60                       0                               0                                20                          nd                    [7]
Horn                                          23             43               nd                 42              45                       9                              17                               22                          nd                   [15]
Piccaluga                                   4             nd               nd                 nd            100                    nd                            nd                              nd               Distinct from
                                                                                                                                                                                                                                                 but closer to
                                                                                                                                                                                                                                                      FL1-3A
                                                                                                                                                                                                                                               than to DLBCL       [24]
Guo                                           14             57                79                 nd             71                      43                             36                              nd                         nd                   [11]
* Cases with antecedent FL1-2 and concomitant DLBCL omitted.
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Can multiple myeloma become a curable disease?
Jesús F. San-Miguel and María-Victoria Mateos 
Servicio de Hematología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain
E-mail: sanmigiz@usal.es or mvmateos@usal.es doi:10.3324/haematol.2011.051169
For decades, multiple myeloma (MM) has been consid-ered a disease of the elderly, with few therapeuticoptions apart from alkylators and corticosteroids.
The treatment goal was disease control, with response
rates of 50%, with occasional complete responses (CRs)
and median survival of 2-3 years.1 In fact, a cure was con-
sidered unattainable. It is possible that this state of affairs,
which has lasted for more than 30 years, is the reason why
the myeloma community has developed a rather conser-
vative outlook.
The introduction of high-dose therapy followed by
autologous stem cell support (HDT/ASCT) produced
three important changes in the myeloma landscape: i) CR
in 15-30% of patients; ii) the possibility of long treatment-
free periods with excellent quality of life (QoL); and iii)
prolongation of survival by one year.2 Nevertheless, the
greatest change has occurred in the last decade with the
discovery of novel agents such as immunomodulatory
drugs (thalidomide and lenalidomide) and proteasome
inhibitors (bortezomib). These have contributed to dou-
bling survival in myeloma patients as compared to the
1990s when only chemotherapy was used.3,4
Despite the fact that, until recently, MM was considered
incurable, the introduction of HDT and novel drugs has
